share_log

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $15

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $15

Needham維持對遞歸製藥的買入,將目標股價下調至15美元
Benzinga ·  2023/11/09 17:56

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $17 to $15.

Needham分析師吉爾·布魯姆維持Recursion Pharmicals(納斯達克股票代碼:RXRX)的買入,並將目標股價從17美元下調至15美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論